EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal Cancer

Sona Chowdhury, Cynthia Gasper, Ann A Lazar, Kathryn Allaire, Teresa M Darragh, Lawrence Fong, Joel M Palefsky

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2025.100918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Sona Chowdhury und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, California. Hauptthemen laut MEDLINE: B7-H1 Antigen, Anus Neoplasms, Programmed Cell Death 1 Receptor, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Foundation for Basic Research, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk human papillomavirus (HPV) is associated with anal high-grade intraepithelial lesion (aHSIL) and anal squamous cell carcinoma (aSCC). The prognostic significance of programmed death-ligand 1 (PD-L1)- expression in aSCC and its impact on overall survival is controversial. ASCC can evade immune surveillance by coopting the PD-L1/programmed cell death-1 (PD-1) immune checkpoint pathway, enhancing tumorigenesis. To assess the potential role of the PD-L1/PD-1 axis on tumor progression, we assessed PD-L1 and PD-1 expression on epithelial cells and immune cells by immunohistochemistry in nonlesional anal tissue (n = 22), aHSIL (n = 22), and aSCC (n = 52) from HIV-negative participants and people living with HIV. PD-L1 expression on epithelial cells was restricted to tumor cells with no expression in nonlesional and HSIL tissues, whereas PD-L1-positive immune cells were present across all 3 diagnostic stages. PD-1 expression was absent on epithelial cells, whereas PD-1-positive immune cells increased along the disease continuum from nonlesional to aSCC. The overall PD-L1 expression on epithelial cells and immune cells measured by the combined positive score (CPS) in aSCC and the aggregate PD-L1 score in nonlesional and HSIL showed a substantial increase from nonlesional to aHSIL to aSCC. In aSCC, PD-L1 expression on immune cells was more prominent than in tumor cells and correlated with increased immune cell infiltration and interferon gamma secretion. Ninety-two percent of aSCC exhibited an adaptive PD-L1 expression pattern characterized by PD-L1 expression on tumor cells, immune cells, or both. HIV status did not affect PD-L1/PD-1 expression in nonlesional, aHSIL, or aSCC. PD-L1 expression in treatment-naive aSCC was associated with improved overall survival. Those with CPS of 0 had a higher risk of death (hazard ratio, 15.2 [95% CI, 3.3-69; P = .0004; log-rank P 0. CPS may indicate the presence of immune activation and serve as a potential prognostic marker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenAnus NeoplasmsProgrammed Cell Death 1 ReceptorBiomarkers, TumorCarcinoma, Squamous CellHumansMaleFemaleMiddle AgedAdultAgedImmunohistochemistryPrognosis

Stichwörter der Autor:innen

anal cancercombined positive scorehot tumorimmunotherapyprogrammed death-ligand 1tumor microenvironment

Substanzen

B7-H1 AntigenCD274 protein, humanProgrammed Cell Death 1 ReceptorPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, California.
  • Department of Pathology, University of California, San Francisco, California.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, California; Department of Preventive and Restorative Dental Sciences, University of California, San Francisco, California.
  • Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California.
  • Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, California. Electronic address: joel.palefsky@ucsf.edu.

Förderung

  • Russian Foundation for Basic Research
  • National Cancer Institute
  • National Institutes of Health
  • Foundation for the National Institutes of Health

Zitieren

APA

Chowdhury, S., Gasper, C., Lazar, A. A., Allaire, K., Darragh, T. M., Fong, L., & Palefsky, J. M. (2026). Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal Cancer. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100918

Vancouver

Chowdhury S, Gasper C, Lazar AA, Allaire K, Darragh TM, Fong L, et al. Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal Cancer. Modern Pathology. 2026. doi:10.1016/j.modpat.2025.100918

BibTeX
@article{Chowdhury2026,
  author = {Chowdhury, Sona and Gasper, Cynthia and Lazar, Ann A and Allaire, Kathryn and Darragh, Teresa M and Fong, Lawrence and Palefsky, Joel M},
  title = {Expression of Programmed Death-Ligand 1 and Programmed Cell Death-1 Across the Anal Neoplasia Disease Continuum and Association With Survival in Anal Cancer},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2025.100918}
}
Kostenlos starten →